Recombinant Human Prostaglandin E2 receptor EP2 subtype (PTGER2)

Where is PTGER2 expressed in the human body and how can this distribution be methodically studied?

PTGER2 demonstrates broad tissue distribution in humans, with notable expression in:

For methodical tissue distribution studies, researchers should employ multi-technique validation approaches including:

• Immunohistochemistry with specific anti-PTGER2 antibodies, comparing expression to normal epithelial cells as a baseline control

• Quantitative RT-PCR to measure mRNA expression levels across tissue panels

• Western blot analysis with validated antibodies to detect protein expression

• Single-cell RNA sequencing for cellular resolution of expression patterns

When conducting IHC studies, researchers should record the fraction of cells showing cytoplasmic PTGER2 overexpression compared to normal cells and establish appropriate cutoffs for positivity, potentially using microsatellite instability (MSI) status as a reference point .

What signaling pathways are activated by PTGER2 and how are they experimentally measured?

PTGER2 activation initiates a specific signaling cascade characterized by:

• Coupling exclusively to Gαs proteins upon ligand binding

• Stimulation of adenylyl cyclase activity

• Increased intracellular cAMP production

• Activation of downstream effectors regulated by cAMP

For experimental measurement of these pathways, researchers can employ:

• ELISA-based cAMP quantification assays following PTGER2 activation

• Fluorescent or luminescent cAMP reporter systems for real-time monitoring

• Phosphorylation assays for downstream effectors such as PKA substrates

• Calcium flux assays to distinguish PTGER2 from other EP receptors (PTGER2 activation typically doesn't induce calcium mobilization)

Unlike other prostaglandin receptors, PTGER2 is thought to alter cell function exclusively through cAMP generation , making this a critical endpoint for confirming selective receptor activation.

What is the experimental evidence for PTGER2's role in reproduction and fertility?

PTGER2 plays crucial roles in reproductive processes, particularly ovulation and fertilization. Multiple lines of experimental evidence support this:

• Knockout mouse models demonstrate that mice lacking functional PTGER2:

  • Show modest reduction in ovulation capacity

  • Exhibit severely impaired fertilization capacity

  • Produce significantly reduced litter sizes

• Mechanistic studies reveal that:

  • PGE2 acts as a key intrafollicular mediator of ovulation across mammalian species

  • The ovulatory LH surge regulates both PGE2 synthesis and PTGER2 expression

  • Different follicular cell types (oocyte, cumulus granulosa, mural granulosa, theca, endothelial) express distinct subsets of the four PTGERs, creating a spatial and temporal map of PGE2 responses

To study PTGER2's reproductive functions, researchers should consider:

• Superovulation protocols in PTGER2-null vs. wild-type animals

• In vitro fertilization assays using oocytes from PTGER2-deficient animals

• Selective PTGER2 agonist (butaprost) administration timing experiments relative to the LH surge

• Immunohistochemical mapping of receptor expression across follicular cell types during different stages of the ovulatory cycle

How does PTGER2 contribute to cancer development and progression?

PTGER2 has been implicated in multiple cancer types, acting as a potential tumor promoter:

• Colorectal cancer studies show:

  • PTGER2 overexpression was detected in 33% (169/516) of colorectal cancer tumors by immunohistochemistry

  • PTGER2 upregulation is associated with inflammatory reactions in the carcinogenic process, particularly in microsatellite instability-high (MSI-high) colorectal cancer

• PTGER2 knockout mouse models demonstrate:

  • Reduced incidence and progression of lung cancer

  • Diminished development of breast cancer

  • Decreased skin cancer occurrence

  • Lower rates of colon cancer

For investigating PTGER2 in cancer research, recommended methodologies include:

• Multivariate logistic regression models to assess independent relationships between PTGER2 expression and other clinicopathological variables

• Kaplan-Meier survival analysis and Cox proportional hazard models to evaluate the prognostic significance of PTGER2 overexpression

• Stratified analysis by microsatellite instability status, LINE-1 methylation, and mutations in cancer-related genes (BRAF, KRAS, PIK3CA)

• Statistical approaches that correct for multiple hypothesis testing (e.g., Bonferroni correction)

What methodological approaches can distinguish between PTGER2-specific effects and those mediated by other prostaglandin receptors?

Distinguishing PTGER2-specific effects requires carefully designed experimental approaches:

• Pharmacological tools:

  • Selective PTGER2 agonists: Butaprost is highly selective for PTGER2 and serves as the gold standard agonist

  • PTGER2 antagonists: While AH6809 is commonly used, it has modest antagonist activity against PTGER1 and PTGER3 as well (limiting specificity)

  • Novel antagonists: PF-0441894 offers over 2000-fold selectivity for PTGER2 compared to other PTGERs and can block both native PGE2 and butaprost activation

• Genetic approaches:

  • PTGER2 knockout models (global or conditional)

  • PTGER2 siRNA or shRNA knockdown

  • CRISPR/Cas9-mediated gene editing of PTGER2

  • Comparison with other PTGER knockout models (PTGER1, PTGER3, PTGER4)

• Signaling pathway discrimination:

  • PTGER2 signals exclusively through cAMP, while other PTGERs use different second messengers

  • PTGER1 activation leads to calcium mobilization

  • PTGER3 typically inhibits adenylyl cyclase

  • PTGER4 increases cAMP (like PTGER2) but can also activate other pathways

Researchers should employ multiple approaches simultaneously for robust verification of PTGER2-specific effects.

What are the optimal conditions for working with recombinant PTGER2 protein in laboratory settings?

For optimal results with recombinant human PTGER2 protein:

• Expression systems:

  • Wheat germ expression systems have proven effective for producing full-length (358 amino acid) functional PTGER2 protein

  • The protein is suitable for SDS-PAGE, ELISA, and Western blot applications

• Storage and handling:

  • Store protein in buffer conditions that maintain the native conformation of the seven transmembrane domains

  • Avoid multiple freeze-thaw cycles which can compromise protein functionality

  • For experiments requiring membrane insertion, consider using liposome reconstitution methods

• Experimental applications:

  • For functional assays, reconstitute in membrane environments or use cell systems expressing the recombinant protein

  • For binding studies, ensure proper folding of the ligand-binding domain

  • For antibody production, use highly purified protein with verified sequence integrity

• Quality control measures:

  • Verify protein identity by mass spectrometry

  • Confirm ligand binding capacity with radiolabeled PGE2

  • Test functional activity through cAMP assays in appropriate cell systems

How should researchers design experiments to investigate PTGER2 expression patterns in pathological tissues?

For robust analysis of PTGER2 expression in pathological contexts:

• Tissue preparation and sampling:

  • Use standardized fixation protocols (e.g., formalin fixation and paraffin embedding)

  • Include normal adjacent tissue as internal controls

  • Consider tissue microarrays for high-throughput analysis across multiple samples

• Immunohistochemical detection:

  • Apply validated anti-PTGER2 antibodies with demonstrated specificity

  • Use rabbit secondary antibody, avidin-biotin complex conjugate, diaminobenzidine, and methyl-green counterstain

  • Maintain slides at 4°C overnight during primary antibody incubation

  • Record the fraction of tumor cells with cytoplasmic PTGER2 overexpression compared to normal colonic epithelial cells

• Expression quantification:

  • Establish clear scoring criteria for PTGER2 positivity

  • Consider using microsatellite instability (MSI) status to determine appropriate cutoffs

  • Use digital image analysis when possible for objective quantification

  • Conduct statistical analysis comparing PTGER2 expression with clinicopathological variables

• Validation approaches:

  • Confirm protein expression findings with mRNA analysis (RT-PCR or RNA-seq)

  • Cross-validate with multiple antibodies targeting different epitopes

  • Include positive and negative controls in each experimental batch

What statistical methods are most appropriate for analyzing PTGER2 expression in clinical samples?

For robust statistical analysis of PTGER2 expression data:

• Descriptive statistics:

  • Clearly report the percentage of samples showing PTGER2 overexpression (e.g., 33% of colorectal tumors)

  • Use histograms or box plots to visualize expression distribution across sample groups

• Correlation with categorical variables:

  • Apply chi-square tests to calculate odds ratios with 95% confidence intervals

  • For multiple hypothesis testing, adjust p-values using Bonferroni correction (e.g., p=0.0029 for 17 comparisons)

• Multivariate analysis:

  • Construct multivariate logistic regression models to assess independent relations between PTGER2 expression and other variables

  • Include relevant covariates such as:

    • Demographic factors (sex, age, BMI)

    • Clinicopathological features (tumor location, grade, components)

    • Molecular characteristics (CIMP, MSI, mutations)

• Survival analysis:

  • Use Kaplan-Meier method and log-rank test to assess survival time distribution by PTGER2 status

  • Construct multivariate, stage-matched Cox proportional hazard models

  • Verify the proportionality of hazard assumption by evaluating time-dependent variables

  • Assess interactions by including cross-product terms in multivariate models

• Data imputation and missing values:

  • For missing categorical data, include cases in a majority category to avoid overfitting

  • Assign separate missing indicator variables to cases with missing information

  • Confirm that excluding cases with missing data doesn't substantially alter results

What are the most common pitfalls and challenges in PTGER2 research?

Researchers should be aware of several key challenges when studying PTGER2:

• Receptor specificity issues:

  • PTGER2 shares 30% amino acid identity with PTGER4, potentially leading to misidentification in older literature

  • Many pharmacological tools lack sufficient selectivity (e.g., AH6809 has activity against PTGER1 and PTGER3)

  • Careful validation of receptor-specific effects is essential

• Expression heterogeneity:

  • PTGER2 expression varies significantly across tissue types and disease states

  • Different cell types within the same tissue may express varying levels of PTGER2

  • Spatial and temporal expression patterns must be carefully mapped

• Methodological limitations:

  • Lack of highly specific antibodies can hamper immunohistochemical studies

  • Global knockout models may not reveal tissue-specific functions

  • Compensatory mechanisms involving other EP receptors may confound results

• Data interpretation challenges:

  • Conflicting results across different experimental models or species

  • Difficulty distinguishing primary from secondary effects of PTGER2 modulation

  • Translating findings from animal models to human physiology and pathology

• Technical considerations:

  • Appropriate controls for receptor activation studies

  • Validation of knockdown or knockout efficiency

  • Careful selection of cell lines with appropriate prostaglandin receptor expression profiles

What emerging approaches might advance our understanding of PTGER2 biology?

Several promising research directions could significantly advance PTGER2 research:

• Structural biology approaches:

  • Cryo-electron microscopy of PTGER2 in complex with ligands and G proteins

  • Structure-based design of more selective agonists and antagonists

  • Investigation of receptor dimerization and higher-order complexes

• Systems biology integration:

  • Multi-omics approaches combining transcriptomics, proteomics, and metabolomics

  • Network analysis of PTGER2-mediated signaling pathways

  • Mathematical modeling of prostaglandin receptor dynamics in complex tissues

• Advanced genetic tools:

  • Tissue-specific and inducible PTGER2 knockout models

  • CRISPR-based screens for PTGER2 modulators

  • Single-cell resolution of PTGER2 function in heterogeneous tissues

• Therapeutic applications:

  • Development of highly selective PTGER2 modulators for clinical applications

  • Investigation of PTGER2 targeting in cancer immunotherapy

  • Exploration of PTGER2's potential in reproductive medicine

• Translational research:

  • Biomarker development based on PTGER2 expression or activation

  • Patient stratification strategies for PTGER2-targeted therapies

  • Pharmacogenomic studies of PTGER2 pathway variants